Now Available: Advancing Gene + Cell Therapies for Cancer Abstracts

Read the most innovative cancer science in the field, with more than 30 pieces of original research! The collection is now available to download via a PDF and to sort via an Excel file on ASGCT.org.

Check out abstracts highlighted below!

• Poster abstracts will be presented during two concurent sessions 8 a.m. – 6:45 p.m on Wednesday, Oct. 16.

• Oral abstracts will be presented 4:10 – 5:25 p.m. on Wednesday, Oct. 16, and 10:45 a.m. – 12 p.m. on Thursday, Oct. 17.

View the abstracts PDF     Sort the abstracts via Excel

Register for #ASGCTAdvancing24

Oral Abstracts

Wednesday, Oct. 16, 4:10 – 5:25 p.m. ET
Thursday, Oct. 17, 10:45 a.m. – 12 p.m. ET

1. Phase 1 Trial of Human Chimeric Antigen Receptor Modified T Cells (HuCART-meso) Administered in Combination with VCN-01 in Patients With Pancreatic and Serous Epithelial Ovarian Cancer
Janos Tanyi, University of Pennsylvania

2. Combining CAR T Cell Therapy with Targeted Proton Beam Radiotherapy
Ugur Uslu, University of Pennsylvania

14. Engineering Allogeneic Cell Immunotherapies in a Single Intervention with the Innovative Pin-pointTM Base Editing Platform
Shannon Hinsdale, Revvity

4. Precision Biomaterials-Mediated Chronic Stimulation Sustains Supernumerary Expansion of Human CAR-T Cells In Vitro
Xiao Huang, Drexel University

5. Single Cell Analysis of Longitudinal CSF from Glioblastoma Patients Post Intrathecally Delivered EGFR-IL13Rα2 CAR T Therapy
Dana Silverbush, PhD, University of Pennsylvania School of Medicine

6. Tracking CARs; Cell Surface Barcoding Novel Multi-targeted CAR T Cell Therapies for High Grade Gliomas
Ryan Cross, PhD, Walter and Eliza Hall Institute of Medical Research Immunology Division

7. The Augmentation of Smac Levels through an Armed Vesicular Stomatitis Virus Enhances Antitumor Immunity by Triggering PANoptosis
Yong Teng, PhD, Emory University School of Medicine

8. ADI-270: An Armored Allogeneic Anti-CD70 CAR γδ T cell Therapy Designed for Enhanced Potency and Persistence Against Multiple Oncology Indications
Shon Green, Adicet Therapeutics

9. Bioreducible LiPBAE miR-590-3p NanomiRs Inhibit Recurrent Glioblastoma Growth and Prolongs Survival
Hernando Lopez-Bertoni, PhD, Johns Hopkins School of Medicine

10. Tumor Associated Mitochondria Antigens (TAMAs) Vaccine Is Effective on Tumor and Tumor Associated Endothelial Cells: From the Mechanisms to the Clinical Validation
Francesca Costabile, PhD, University of Pennsylvania

View the abstracts PDF     Sort the abstracts via Excel

Register for #ASGCTAdvancing24

Related Articles